An R/S can work out correctly with the proper catalysts in line. If the BLA timeline is not delayed any further, an R/S and uplist would do well to bring CYDY into the mainstream market. But again, the BLA has to get submitted on time and a licensing agreement with payments has to be made.

I was in a stock a few years ago that did an R/S and uplisted before a data release. The stock nearly quadrupled during the R/S, uplist and run into data. The institutions who purchased the stock helped that run and owned millions of shares after.